Report
EUR 9106.00 For Business Accounts Only

Singtel (Buy, TP: S$4.6, +52%) Highlights from Investor Day 2024; positive comments around shareholder remuneration likely to extend the rally.

Singtel held its Investor Day today. Overall tone was more positive relative to last year as the core is beginning to bear fruits from its cost-out initiatives in addition to the clear capex and shareholder remuneration pathway as echoed by its ST28 strategy. The stock remains one of our top picks despite the recent rally as we continue to see good value.
Underlying
Singapore Telecommunications Limited

Singapore Telecommunications is engaged in the operation and provision of telecommunications systems and services, and investment holding. Co. provides a range of multimedia and Information and communications technology solutions, including voice, data and video services over fixed and wireless platforms. Within both Singapore and Australia, Co. provides mobile communications, data and Internet, national telephone, information technology and engineering, sale of equipment, international telephone and pay television. Co.'s key businesses include: Group Consumer, Group Digital L!fe, and Group Information and communications technology.

Provider
New Street Research
New Street Research

Provided by our team of experienced analysts, our work is idea driven, based on independence of thought, sector expertise, and firmly focussed on fundamentals and valuation.

New Street Research is an independent, partner-owned, research firm specialising in equity and debt research. Our equity research embraces the following sectors:

  • Pan European Telecom Services and Cable
  • US Telecoms, Cable, Satellite and Towers
  • Global Emerging Market Telecoms
  • Japan Telecoms
  • Asian Internet
  • Pan European Healthcare
  • Global healthcare thematic research

We provide debt research on:

  • Pan European Telecom Services and Cable


Analysts
Chris Hoare

Other Reports on these Companies
Other Reports from New Street Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch